BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.

The vaccine demonstrated efficacy in mild, moderate, and severe COVID-19 of 77.8% with efficacy against severe disease of 93.4%.

Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.

A resume is your introduction to a potential employer, and as the saying goes, “You only get one chance to make a good first impression.” Follow these resume writing tips today.

With the outbreak of the COVID-19 pandemic, companies are transitioning to remote work.

Oncopeptides AB announces updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have received 2 – 4 prior lines of therapy.

Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve.

On 21 July, at 08:00 CEST, Swedish Orphan Biovitrum AB will publish its report for the second quarter 2021.

Evaxion Biotech A/S, a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of cancer immunotherapy EVX-02 in adjuvant melanoma.